Pherecydes Pharma Announces Its Participation in a Number of Major Scientific and Investor Conferences

NANTES, France–(BUSINESS WIRE)–Regulatory News:

Pherecydes Pharma (FR0011651694 – ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that its management team participated or will participate in the following scientific and investor events:

Scientific conferences

Investor conferences

• Portzamparc BNP Paribas Biotech & Health seminarOctober 4, 2022 (virtual event)This event, organized by Portzamparc, a subsidiary of the BNP Paribas Group, gives French and international investors the opportunity to interact with executives from listed healthcare companies.

Next financial publication:

• 2022 half-year results: Thursday, October 27, 2022, after market

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied in several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.

For more information, www.pherecydes-pharma.com

Disclaimer

This press release contains non-factual elements, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of the Company. They incorporate known and unknown risks and uncertainties that could result in significant differences in results, profitability and expected events. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, counsels and employees have not verified the accuracy of, and make no representations or warranties about, statistical information or forecast information contained within this news release and that originates or is derived from third party sources or industry publications; these statistical data and forecast information are only used in this press release for information purposes. Finally, this press release may be drafted in French and in English. In the event of differences between the two texts, the French version will prevail.

Contacts

Pherecydes Pharma
Thibaut du Fayet

Deputy CEO

investors@pherecydes-pharma.com

NewCap
Dusan Oresansky / Nicolas Fossiez

Investor Relations

pherecydes@newcap.eu
T.: +33 1 44 71 94 92

NewCap
Arthur Rouillé

Media Relations

pherecydes@newcap.eu
T.: +33 1 44 71 00 15